D.E. Shaw & Co
IBER.U

D.E. Shaw & Co’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

D.E. Shaw & Co’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-55,587
Closed -$559K – 5421
2021
Q2 		$559K Buy
55,587
+30,587
+122% +$306K ﹤0.01% 3977
2021
Q1 		$247K Buy
+25,000
New +$250K ﹤0.01% 3784

Other funds holding IBER.U

HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's IBER.U Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2021, closing a stake of 55,587 shares — an estimated $559K sold.

D.E. Shaw & Co first reported a position in IBER.U in Q1 2021 and held it in 2 quarters. The position peaked at $559K in Q2 2021. 27 funds tracked by Wall St. Rank hold IBER.U as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 55,587 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2021, an estimated $559K.
  • D.E. Shaw & Co first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $559K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.